Brian Walter Granda

USPTO Granted Patents = 10 (Patent Applications = 18)

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 33(Granted Patents)

Location History:

Cambridge, MA (US) (2019)
Salisbury, MA (US) (2020 - 2024)

Company Filing History:

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),

2. 12221481 - CD19 binding molecules and uses thereof (2025-02-11),

3. 12037378 - Variant CD58 domains and uses thereof (2024-07-16),

4. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),

5. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),

6. 11667691 - Treatment of cancer using chimeric CD3 receptor proteins (2023-06-06),

7. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),

8. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),

9. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2020-01-07),

10. 10287354 - Regulatable chimeric antigen receptor (2019-05-14),

Title: Brian Granda: Inspiring Innovations in Disease Treatment

Introduction:

Brian Granda, a passionate inventor based in Salisbury, MA (US), is a trailblazer in the field of biotechnology and healthcare innovations. His relentless pursuit of excellence has not only led to groundbreaking inventions but has also inspired the next generation of inventors.

Latest Patents:

With one patent to his name, Brian Granda has made a significant impact in the medical field. His patent titled "Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain" provides innovative compositions and methods for treating diseases associated with CD20 or CD22 expression.

Career Highlights:

Throughout his career, Brian Granda has worked with prestigious organizations such as Novartis AG and the University of Pennsylvania. These experiences have not only enriched his knowledge but have also provided him with the platform to translate his innovative ideas into reality.

Collaborations:

Brian Granda has collaborated with talented individuals such as Barbara Brannetti and Jennifer Brogdon. Together, they have worked tirelessly to develop cutting-edge technologies that have the potential to revolutionize the healthcare industry.

Conclusion:

In conclusion, Brian Granda's dedication to innovation and his commitment to pushing the boundaries of technological advancement continue to shape the future of healthcare. His contributions have not gone unnoticed and serve as a beacon of inspiration for aspiring inventors worldwide.

This text is generated by artificial intelligence and may not be accurate.